Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: HMG CoA reductase inhibitors controlled release - Oxford Pharmascience

Next Previous
Drug Profile

Research programme: HMG CoA reductase inhibitors controlled release - Oxford Pharmascience

Alternative Names: Atorvastatin - Oxford Pharmascience; OXP 003; OXP 004; Safestat™ Atorvastatin; Safestat™ Simvastatin; Simvastatin - Oxford Pharmascience

Latest Information Update: 28 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford Pharmascience
  • Class Amides; Cardiovascular therapies; Fluorobenzenes; Heptanoic acids; Naphthalenes; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 28 Mar 2023 Discontinued - Preclinical for Cardiovascular disorders in United Kingdom (PO)
  • 28 Nov 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders in United Kingdom (PO)
  • 09 Nov 2016 Development of a new colon-targeted formulation of atorvastatin for cardiovascular disorders is ongoing in United Kingdom

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top